Cita APA

Heidler, C. L., Roth, E. K., Thiemann, M., Blattmann, C., Perez, R. L., Huber, P. E., . . . Kulozik, A. E. (2019). Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib. Int J Cancer.

Citación estilo Chicago

Heidler, Christopher L., et al. "Prexasertib (LY2606368) Reduces Clonogenic Survival By Inducing Apoptosis in Primary Patient‐derived Osteosarcoma Cells and Synergizes With Cisplatin and Talazoparib." Int J Cancer 2019.

Cita MLA

Heidler, Christopher L., et al. "Prexasertib (LY2606368) Reduces Clonogenic Survival By Inducing Apoptosis in Primary Patient‐derived Osteosarcoma Cells and Synergizes With Cisplatin and Talazoparib." Int J Cancer 2019.